focus -WSS

focus

author：knowledge 2025-10-01 22:49:49 - browse：1

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Timeline: Key moments in fight for gay rights

focus

WSS

Stanford president's case begs question: Who takes blame?

Why Congress must ban federal programs from using QALYs

Sea level rise could wash away turtle breeding grounds around the world, researchers say

I learned firsthand about improving diversity in clinical trials

Timeline: Key moments in fight for gay rights

Texas Department of Public Safety speaks out on migrant abuse allegations

leisure time

focus

focus

Anesthesiologist group: stop taking Ozempic before surgery

I learned firsthand about improving diversity in clinical trials

New air purifier tech could be key to improving indoor air quality

The thinking behind the controversial eating disorder chatbot Tessa

Hepatitis C has a cure — but many Americans still lack access to it

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Altering the blood type of lungs raises potential for universal organs for transplants

Wildfire smoke exposes gaps in outdoor worker protections

Timeline: Key moments in fight for gay rights

focus

Xenotransplantation trials will require adjusting expectations, experts say

7 more heat

Biogen nominates mother of director’s child to replace him on board

I learned firsthand about improving diversity in clinical trials

Hospitals struggle to profit from CAR

Millions may soon lose Medicaid when they don't have to

focus

leisure time

knowledge

leisure time